Citius Pharmaceuticals
Presença
Citius Pharmaceuticals é uma empresa listada sob o símbolo CTXR (US).
Executivos
Veja o organograma con seus 18 executivos principais
Biografias mais buscadas da Citius Pharmaceuticals
- Leonard Mazur, Chairman of the Board and Chief Executive Officer
- Myron Holubiak, Vice Chairman of the Board
- Carol Webb, Director
Criar um alerta
para seguir os movimentos de executivos da Citius Pharmaceuticals.
Farmacêutica
Citius Pharmaceuticals possui 1.863 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Citius Pharmaceuticals
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
- Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
- Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
- Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
- Citius Pharmaceuticals, Inc. - Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
- View more press releases Close
Redes sociais sobre Citius Pharmaceuticals
- Citius Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Citius Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Leonard Mazur 
Ligue para a Citius Pharmaceuticals em +1 617...
